Recent Updates
Recently added Catalysts

IDH-Mutant Astrocytoma, Grade 2: 3 biotech companies with clinical-stage programmes

OncologyConcentrated betData as of 2026-09-04

Competitors3in the clinic
Median market cap$2.5Buniverse median $1.20B
Allocated capital$2.0B$8.7B competing
Phase 3 or filed11 mid, 1 early
Pure plays0this indication only
Capital rank97/299crowding rank 67

IDH-Mutant Astrocytoma, Grade 2 is a concentrated bet: only 3 US-listed developers are in the clinic, and the median one is worth $2.5B against a $1.20B universe median.

Scarcity is doing the work in that number. A thin field means an approval is shared with fewer rivals, and the market pays a premium for that position.

1 of the 3 is in Phase 3 or filed, and 2 dated catalysts fall in the next 12 months, so this ranking is likely to move.

$2.0B of allocated capital sits in IDH-Mutant Astrocytoma, Grade 2, ranking it 97th of 299 indications by the money committed to it.

Companies developing drugs for IDH-Mutant Astrocytoma, Grade 2 3

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
TNGXTango TherapeuticsVorasidenibPhase 31$3.8BNo5 23 Oct 2026
NUVBNuvation BioSafusidenibPhase 21$2.4BNo3 26 Oct 2026
HCMHUTCHMED (China)HMPL-306Phase 11$2.5BNo6No dated event

Sorted by phase, then by market capitalisation. Ticker links open the company profile. TNGX holds 44% of the $8.7B competing in this indication.

Why IDH-Mutant Astrocytoma, Grade 2 is a concentrated bet

Few competitors, each one large. The market pays a scarcity premium to compete here.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. IDH-Mutant Astrocytoma, Grade 2 has 3 competitors and a median of $2.5B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

BRAF V600 Mutated Melanoma1 company · $1.9B · median $5.7BUncontestedMetastatic Solid Tumors1 company · $1.9B · median $5.7BUncontestedNon-Hodgkin's Lymphoma7 companies · $1.7B · median $239MKnife fightGastrointestinal Stromal Tumor3 companies · $2.3B · median $1.6BConcentrated betMelanoma4 companies · $2.3B · median $2.6BConcentrated betPancreatic Cancer9 companies · $2.4B · median $371MKnife fightChronic Myelogenous Leukemia2 companies · $2.4B · median $3.0BConcentrated betDesmoid Tumor1 company · $1.5B · median $3.1BUncontested

IDH-Mutant Astrocytoma, Grade 2 pipeline questions

Which biotech companies are developing drugs for IDH-Mutant Astrocytoma, Grade 2?

Tango Therapeutics (TNGX, Vorasidenib, Phase 3); Nuvation Bio (NUVB, Safusidenib, Phase 2); HUTCHMED (China) (HCM, HMPL-306, Phase 1). Those are the 3 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in IDH-Mutant Astrocytoma, Grade 2.

How advanced is the IDH-Mutant Astrocytoma, Grade 2 pipeline?

Of the 3 clinical-stage programmes in IDH-Mutant Astrocytoma, Grade 2, 1 is in Phase 3 or filed, 1 is in mid-stage development and 1 is in early-stage development.

How much is the typical IDH-Mutant Astrocytoma, Grade 2 biotech company worth?

The median company developing a drug for IDH-Mutant Astrocytoma, Grade 2 is worth $2.5B, against a median of $1.20B across the whole universe. $2.0B of allocated capital sits in the indication, ranking it 97th of 299.

When is the next IDH-Mutant Astrocytoma, Grade 2 catalyst?

The next dated catalyst in IDH-Mutant Astrocytoma, Grade 2 is TNGX on 23 Oct 2026. 2 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map